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Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older
Abstract
BACKGROUND A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster
subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B
adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated
with placebo. A second trial was performed concurrently at the same sites and examined the safety and
efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS This randomized, placebocontrolled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older.
Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered
intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was
assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS In
ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950
participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster
occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years).
Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001)
and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older
(89.1%). In pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70
(16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to 94.5; P<0.001),
and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI, 68.7 to 97.1; P<0.001). Solicited
reports of injection-site and systemic reactions within 7 days after injection were more frequent among
HZ/su recipients than among placebo recipients (79.0% vs. 29.5%). Serious adverse events, potential
immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups.
CONCLUSIONS In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic
neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and
ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229.)
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a bs t r ac t
BACKGROUND

A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster
subunit vaccine (HZ/su) containing recombinant varicella–zoster virus glycoprotein E and
the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2%
lower than that associated with placebo. A second trial was performed concurrently at
the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age
or older (ZOE-70).
METHODS

This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and
involved adults 70 years of age or older. Participants received two doses of HZ/su or
placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine
efficacy against herpes zoster and postherpetic neuralgia was assessed in participants
from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50.
RESULTS

In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received
either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up
period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo
recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was
89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001) and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older (89.1%). In
pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70
(16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to
94.5; P<0.001), and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI,
68.7 to 97.1; P<0.001). Solicited reports of injection-site and systemic reactions within
7 days after injection were more frequent among HZ/su recipients than among placebo
recipients (79.0% vs. 29.5%). Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups.

The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr.
Heineman at Genocea Biosciences, Cambridge Discovery Park, 100 Acorn Park
Dr., 5th Floor, Cambridge, MA 02140, or
at thomas.heineman@genocea.com.
* A complete list of investigators in the
Zoster Efficacy Study in Adults 70 Years
of Age or Older (ZOE-70) Study Group is
provided in the Supplementary Appendix, available at NEJM.org.
Drs. Cunningham and Lal contributed
equally to this article. Authors from Dr.
Godeaux to Dr. Zahaf (listed alphabetically) also contributed equally, as did authors from Dr. Ahonen to Dr. Yeo (listed
alphabetically).
N Engl J Med 2016;375:1019-32.
DOI: 10.1056/NEJMoa1603800
Copyright © 2016 Massachusetts Medical Society.

CONCLUSIONS

In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals;
ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229.)
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erpes zoster, or shingles, results
from the reactivation of latent varicella–
zoster virus (VZV) and typically manifests as a vesicular, painful dermatomal rash.1,2
The most common complication of herpes zoster, postherpetic neuralgia, manifests as chronic
neuropathic pain that can greatly limit daily activities.1,3-6
The overall incidence of herpes zoster is 2.0 to
4.6 cases per 1000 person-years but increases
with age to 10.0 to 12.8 per 1000 person-years
among persons 80 years of age or older.7-10 Similarly, the incidence of postherpetic neuralgia
also increases with age.10-13
Antiviral therapy can reduce the duration of
herpes zoster rash but has not been shown to
decrease the incidence of postherpetic neuralgia.14-17 Vaccination is therefore an attractive option to reduce the disease burden due to herpes
zoster and its complications in older adults.
Currently, a live attenuated herpes zoster vaccine
(Zostavax, Merck) is approved for use in adults
50 years of age or older and is recommended for
adults 60 years of age or older.2,18,19
An investigational herpes zoster subunit vaccine (HZ/su; GSK Vaccines) containing VZV glycoprotein E and the AS01B adjuvant system is being
evaluated for the prevention of herpes zoster and
postherpetic neuralgia in adults 50 years of age
or older.20-25 A previous trial (Zoster Efficacy Study
in Adults 50 Years of Age or Older [ZOE-50])
showed that HZ/su had a vaccine efficacy against
herpes zoster of 97.2%, which was consistent
across all age groups.26 Although 24% of the
participants in ZOE-50 were 70 years of age or
older, the trial was not intended to definitively
assess vaccine efficacy against herpes zoster or
postherpetic neuralgia in this age group. Therefore, in parallel with ZOE-50, we conducted a
second trial involving only adults who were 70
years of age or older (Zoster Efficacy Study in
Adults 70 Years of Age or Older [ZOE-70]) to assess vaccine efficacy against herpes zoster in this
population; we also estimated vaccine efficacy
against postherpetic neuralgia in the combined
population (i.e., from ZOE-50 plus ZOE-70) of
adults 70 years of age or older and adults 50
years of age or older.
Here, we present the results of ZOE-70. We
also present the results of the prespecified
pooled analyses of vaccine efficacy against herpes
zoster and postherpetic neuralgia among participants in ZOE-70 and ZOE-50.
n engl j med 375;11
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Me thods
Study Design

ZOE-70 was a randomized, placebo-controlled,
phase 3 trial conducted in 18 countries in Europe, North America, Latin America, and Asia–
Australia to evaluate the efficacy, immunogenicity, and safety of HZ/su in adults 70 years of age
or older. The investigators were unaware of the
study-group assignments during the trial. This
trial had the same design as ZOE-50 and was
conducted concurrently at the same sites.26
The trial protocol, available with the full text
of this article at NEJM.org, was approved by the
appropriate independent ethics committee or
institutional review board at each study center.
Written informed consent was obtained from all
participants before study entry. ZOE-70 was conducted in accordance with the provisions of the
Declaration of Helsinki and the International
Conference on Harmonisation Good Clinical
Practice guidelines. During the study, potential
research compliance issues were investigated,
and appropriate actions were taken when needed.
ZOE-70 was monitored by an independent data
and safety monitoring committee that met regularly during the course of the study to review all
safety data in an unblinded manner, as described previously for ZOE-50.26
Medical writing was provided by 4Clinics,
France, with funding support from GlaxoSmithKline Biologicals. All the authors reviewed and
approved the final submitted version of the
manuscript. The last author vouches for the completeness and accuracy of all the data and the
analyses presented and for the fidelity of the trial
to the protocol.
Eligibility, Randomization, and Blinding

Adults 70 years of age or older were eligible for
inclusion in the trial unless they had a history of
herpes zoster, had previously been vaccinated
against varicella or herpes zoster, or had an
immunosuppressive condition (see the Supplementary Appendix, available at NEJM.org, for a
complete list of inclusion and exclusion criteria).
Participants who were 70 years of age or older
were first randomly assigned to either ZOE-5026
or ZOE-70 and then were randomly assigned in
a 1:1 ratio to either the HZ/su group or the placebo group with the use of an online centralized
randomization system. Participants were stratified according to region (Asia and Australia,
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Europe, Latin America, and North America) and
age group (70 to 79 years vs. ≥80 years [in a 3:1
ratio]). The investigators, participants, and persons responsible for evaluating the study end
points were unaware of whether HZ/su or placebo had been administered.
Vaccination

lower than 37.5°C, 1 for 37.5°C to 38.0°C, 2 for
38.1°C to 39.0°C, and 3 for higher than 39.0°C
(the preferred route for recording temperature
was oral). All other symptoms were scored as 0 for
absent, 1 for easily tolerated, 2 for interferes
with normal activity, and 3 for prevents normal
activity.
Unsolicited reports of adverse events were
recorded for 30 days after each dose for all participants. All serious adverse events were recorded for all participants for 12 months after
the second dose. Serious adverse events that
were considered to be related to the study vaccine or to trial participation, events resulting in
death, and potential immune-mediated diseases
were evaluated in all participants throughout the
trial.

HZ/su contains 50 μg of recombinant VZV glycoprotein E and the liposome-based AS01B adjuvant
system (which contains 50 μg of 3-O-desacyl-4′monophosphoryl lipid A [MPL] and 50 μg of
Quillaja saponaria Molina, fraction 21 [QS21, licensed by GSK from Antigenics, a subsidiary of
Agenus]). Vaccine or placebo (0.9% saline solution) was administered (0.5 ml) into the deltoid
muscle at month 0 and month 2. Participants
were to be followed for at least 30 months after
the second dose through monthly contacts and Suspected Cases of Herpes Zoster
annual clinic visits.
A suspected case of herpes zoster was defined as
new unilateral rash with pain (broadly defined
Trial End Points
to include allodynia, pruritus, or other abnormal
The primary objective of ZOE-70 was to evaluate sensations) that had no alternative diagnosis.
the efficacy of HZ/su, as compared with placebo, Suspected cases of herpes zoster were evaluated
in reducing the risk of herpes zoster among as described previously.26 Lesion samples were
adults 70 years of age or older. The primary ob- obtained from patients with suspected herpes
jectives of the pooled analysis involving partici- zoster for polymerase-chain-reaction (PCR) analypants from ZOE-50 and ZOE-70 were to evaluate sis. A suspected case was confirmed as herpes
the efficacy of the vaccine, as compared with zoster if the PCR assay was positive for VZV. The
placebo, in reducing the risk of herpes zoster case was classified as not herpes zoster if the
and the risk of postherpetic neuralgia in the PCR assay was VZV-negative and β-actin–posioverall population of participants 70 years of age tive (control). If the PCR results were indetermior older from the two studies. The secondary nate (VZV-negative and β-actin–negative) or if
objectives included the evaluation of vaccine ef- samples were not available, the final diagnosis
ficacy against postherpetic neuralgia among was determined by unanimous agreement among
participants 50 years of age or older and the the five members of an ascertainment commitevaluation of vaccine safety and reactogenicity. tee, the members of which were unaware of the
(A complete list of objectives is provided in the study group assignments. If the committee opinSupplementary Appendix.)
ion was not unanimous, the case was classified
as inconclusive and was considered not to be
Evaluation of Safety and Reactogenicity
herpes zoster for the purposes of the statistical
In ZOE-70, a randomly selected subgroup of age- analyses.
stratified participants recorded injection-site reactions (pain, redness, and swelling) and systemic Assessment of Postherpetic Neuralgia Cases
reactions (fatigue, fever, gastrointestinal symp- Participants with a suspected case of herpes
toms, headache, myalgia, and shivering) on diary zoster were asked to attend a schedule of assesscards for 7 days after each injection. Redness and ment visits and to complete the Zoster Brief Pain
swelling at the injection site were scored as 0 if Inventory27 questionnaire daily for 28 days and
the affected area was less than 20 mm in diame- weekly thereafter, until the participant had been
ter, 1 if the affected area was 20 to 50 mm, 2 if the pain-free for 4 weeks or for at least 90 days after
affected area was more than 50 to 100 mm, and the onset of the rash. The “worst pain” score
3 if the affected area was more than 100 mm. (item 3: “Please rate your pain by circling the
Fever was scored as 0 for a body temperature one number that best describes your pain at its
n engl j med 375;11
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worst in the last 24 hours,” rated on a scale of
0 to 10, with higher numbers indicating worse
pain) was used to determine whether a participant had postherpetic neuralgia.27 As in previous
studies, postherpetic neuralgia was defined as a
worst pain score of 3 or higher for pain that
persisted or developed more than 90 days after
the onset of herpes zoster rash.19,28
Statistical Analysis

Safety was analyzed in the total vaccinated cohort, which included all participants who could
be evaluated and who had received at least one
dose of HZ/su or placebo. Efficacy was analyzed in the total vaccinated cohort and in the
modified vaccinated cohort (the primary cohort
for the efficacy analysis), which excluded participants who did not receive the second dose
or who had a confirmed herpes zoster episode
within 1 month (30 days) after the second dose.
All the analyses included participants 70 years
of age or older, with the exception of the analysis of vaccine efficacy against postherpetic neuralgia, which included participants 50 years of age
or older.
Vaccine efficacy was defined as 1 minus the
ratio of herpes zoster incidence in the HZ/su
group to that in the placebo group, multiplied
by 100. All significance tests were two tailed.
P values of 0.05 or less were considered to indicate statistical significance. All statistical analyses were performed with SAS software, version
9.3 (SAS Institute), and StatXact software, version 9.0 (Cytel).

R e sult s
Study Population

Participants were enrolled in ZOE-70 between
August 2, 2010, and July 21, 2011. The last study
visit was on July 24, 2015. A total of 14,816 participants were enrolled and underwent randomization, of whom 916 were excluded from all
analyses; 865 of these participants were excluded
because of deviations from Good Clinical Practice standards at a study center (see the Supplementary Appendix). The remaining 13,900 participants constituted the total vaccinated cohort,
13,163 of whom (94.7%) were included in the
modified vaccinated cohort (Fig. 1). Most participants (94.4% of HZ/su recipients and 95.6%

1022
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of placebo recipients) received both doses. In the
pooled analysis of participants from ZOE-70 and
ZOE-50, 17,531 participants 70 years of age or
older were included in the total vaccinated cohort, and 16,596 were included in the modified
vaccinated cohort (Fig. S1 in the Supplementary
Appendix).
In ZOE-70, the demographic characteristics of
the participants at baseline were similar in the
two groups (Table S1 in the Supplementary Appendix). A total of 54.0% of the participants
were from Europe, 76.9% were white, and 54.9%
were female. The mean age of the participants
at study entry was 75.6 years (range, 62 to 96
years). Four participants younger than 70 years
of age were erroneously enrolled in ZOE-70 (3 were
69 years of age, and 1 was 62 years of age).
These participants were included in the cohort
of participants 70 to 79 years of age for all
analyses. Overall, 3066 participants (22.1%) were
80 years of age or older, and 76 (0.5%) were 90
years of age or older. The demographic characteristics of the participants at baseline were also
similar in the two groups in the pooled population of participants 70 years of age or older from
ZOE-70 and ZOE-50.26
Vaccine Efficacy against Herpes Zoster
in Adults 70 Years of Age or Older

In the ZOE-70 total vaccinated cohort, 432 suspected episodes of herpes zoster were reported,
270 of which were confirmed as herpes zoster
(Fig. S2 in the Supplementary Appendix). Of the
270 confirmed cases, 246 occurred in the modified vaccinated cohort: 23 in HZ/su recipients
and 223 in placebo recipients, after a mean follow-up period of 3.7 years (Table 1). The incidence
of herpes zoster per 1000 person-years was 0.9
in the HZ/su group and 9.2 in the placebo group,
for an overall vaccine efficacy of 89.8% (95%
confidence interval [CI], 84.2 to 93.7; P<0.001).
Vaccine efficacy did not differ significantly between the two age groups (90.0% among participants 70 to 79 years of age and 89.1% among
participants ≥80 years of age). In a time-to-event
analysis, the cumulative incidence of herpes zoster was lower in the HZ/su group than in the
placebo group, in both the modified and the
total vaccinated cohorts (Fig. 2A and 2C).
In the pooled analysis of participants 70 years
of age or older from ZOE-70 and ZOE-50, a total
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14,816 Participants were enrolled and
underwent randomization
13 Did not receive vaccine
or placebo

14,803 Received vaccine or placebo

903 Had Good Clinical Practice
violation or other issue
13,900 Could be evaluated
10,834 Were 70–79 yr of age
3,066 Were ≥80 yr of age

Total
Vaccinated
Cohort

6950 Had been assigned to receive HZ/su
and received dose 1 (month 0)
5414 Were 70–79 yr of age
1536 Were ≥80 yr of age

6950 Had been assigned to receive placebo
and received dose 1 (month 0)
5420 Were 70–79 yr of age
1530 Were ≥80 yr of age
305 Did not receive placebo
dose 2
4 Did not receive placebo
according to protocol
8 Received wrong intervention
11 Had herpes zoster develop
<30 days after dose 2

392 Did not receive vaccine
dose 2
3 Did not receive vaccine
according to protocol
12 Received wrong intervention
4 Had herpes zoster develop
<30 days after dose 2

Modified
Vaccinated
Cohort

6541 Were included in modified vaccinated
cohort
5114 Were 70–79 yr of age
1427 Were ≥80 yr of age

6622 Were included in modified vaccinated
cohort
5189 Were 70–79 yr of age
1433 Were ≥80 yr of age

Figure 1. Enrollment and Randomization.
After enrollment, one study center was closed because of Good Clinical Practice violations, and one study center
was closed for financial reasons (see the Supplementary Appendix). All participants who had been enrolled at these
centers were excluded from all analyses. An additional four participants were excluded because of issues with informed consent. Some participants in the total vaccinated cohort had more than one reason for being excluded
from the modified vaccinated cohort. HZ/su denotes herpes zoster subunit vaccine.

of 25 confirmed cases of herpes zoster occurred
in HZ/su recipients, as compared with 284 cases
in placebo recipients, which resulted in a vaccine
efficacy of 91.3% against herpes zoster (95% CI,
86.8 to 94.5%) (Table 1). Vaccine efficacy did not
differ significantly between the two age groups
(91.3% in participants 70 to 79 years of age and
91.4% in participants ≥80 years of age); the results were similar in the total vaccinated cohort
(Table S2 in the Supplementary Appendix). The
cumulative incidence of herpes zoster was lower
in the HZ/su group than in the placebo group

n engl j med 375;11

(Fig. 2B and 2D). Vaccine efficacy was 97.6%
during year 1, 92.0% during year 2, 84.7% during year 3, and 87.9% during year 4 after the
second vaccination (Table 1).
Vaccine Efficacy against Postherpetic
Neuralgia

In the pooled modified vaccinated cohort that
included all participants 50 years of age or older,
postherpetic neuralgia developed in 4 of 32 HZ/su
recipients and in 46 of 477 placebo recipients with
herpes zoster, during a mean follow-up period
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6,468
1,782

70–79 yr

≥80 yr

7

7,426

8,250
13,881

≥70 yr¶

≥50 yr

Pooled ZOE-70 and ZOE-50

Postherpetic neuralgia

4

8,039
7,736

2

3

4

4

7
9

8,250

1

2

6

53,171.5

30,760.3

7,040.3

7,612.2

7,916.9

8,156.2

6,314.6

24,410.9

30,725.5

5,615.9

6,043.5

6,281.0

6,464.7

5,058.5

19,346.5

24,405.1

person-yr

0.1

0.1

1.0

1.2

0.9

0.2

1.0

0.8

0.8

1.1

1.5

1.0

0.3

1.2

0.9

0.9

cases/1000
person-yr

Incidence
Rate

6,622

14,035

8,346

7,267

7,661

8,024

8,346

1,792

6,554

8,346

5,776

6,076

6,372

6,622

1,433

5,189

46

36

56

58

87

83

68

216

284

39

48

68

68

54

169

223

Cases

number

Participants

53,545.0

30,942.0

6,859.6

7,488.4

7,860.5

8,206.2

6,151.9

24,262.8

30,414.7

5,473.2

5,943.0

6,240.4

6,511.2

4,920.3

19,247.5

24,167.8

person-yr

Cumulative
Follow-up
Period‡

Placebo Group

0.9

1.2

8.2

7.7

11.1

10.1

11.1

8.9

9.3

7.1

8.1

10.9

10.4

11.0

8.8

9.2

cases/1000
person-yr

Incidence
Rate

91.2 (75.9 to 97.7)

88.8 (68.7 to 97.1)

87.9 (73.3 to 95.4)

84.7 (69.0 to 93.4)

92.0 (82.8 to 96.9)

97.6 (90.9 to 99.8)

91.4 (80.2 to 97.0)

91.3 (86.0 to 94.9)

91.3 (86.8 to 94.5)

85.1 (64.4 to 94.9)

81.6 (61.9 to 92.1)

91.3 (79.9 to 96.9)

97.0 (88.8 to 99.7)

89.1 (74.6 to 96.2)

90.0 (83.5 to 94.4)

89.8 (84.2 to 93.7)

% (95% CI)

Vaccine Efficacy†

of

19

25

6

9

6

2

6

17

23

Cases

Cumulative
Follow-up
Period‡

HZ/su Group
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Year§

8,250

Overall

Age group

Pooled ZOE-70 and ZOE-50

6,541
6,379

1

2

Year§

6,541

Overall

number

Participants

70–79 yr

Age group

ZOE-70

Herpes zoster

Condition and Cohort

Table 1. Vaccine Efficacy against the First or Only Episode of Herpes Zoster and Postherpetic Neuralgia in the Modified Vaccinated Cohort.*

The

m e dic i n e

September 15, 2016

The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF WOLLONGONG on October 19, 2016. For personal use only. No other uses without permission.
Copyright © 2016 Massachusetts Medical Society. All rights reserved.

*	The modified vaccinated cohort excluded participants who did not receive the second dose of the herpes zoster subunit vaccine (HZ/su) or placebo or who had a confirmed episode of
herpes zoster within 1 month (30 days) after the second dose.
†	Vaccine efficacy was calculated by means of the Poisson method. Vaccine efficacy in each age group was adjusted for region, and overall vaccine efficacy was adjusted for age group and
region. P<0.001 for all comparisons of the efficacy against herpes zoster of the vaccine versus placebo. For the comparison of efficacy against postherpetic neuralgia of the vaccine versus placebo, P<0.001 in the ≥50-yr, ≥70-yr, and 70–79-yr age groups and P = 0.008 in the 50–59-yr age group; the numbers of cases in the placebo group were not sufficient to obtain a
significant result in the 60–69-yr (P = 0.51) and ≥80-yr (P = 0.18) age groups.
‡	Data were censored at the time of the first confirmed diagnosis of herpes zoster or postherpetic neuralgia.
§	Year 1 is defined as the period from 30 to 395 days after the second vaccination, year 2 as the period from 396 to 760 days after the second vaccination, year 3 as the period from 761 to
1125 days after the second vaccination, and year 4 as the period of more than 1125 days after the second vaccination to the last contact date.
¶	The assessment of vaccine efficacy for the prevention of postherpetic neuralgia in participants ≥70 years of age was the primary objective of the pooled analyses.
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of 3.8 years. The incidence of postherpetic neuralgia per 1000 person-years was 0.1 in the HZ/su
group and 0.9 in the placebo group, for a vaccine
efficacy of 91.2% among adults 50 years of age or
older (95% CI, 75.9 to 97.7%; P<0.001) (Table 1).
Postherpetic neuralgia did not develop in any
HZ/su recipients younger than 70 years of age.
Among participants 70 years of age or older,
vaccine efficacy against postherpetic neuralgia
was 88.8% (95% CI, 68.7 to 97.1%; P<0.001)
(Table 1, and Fig. S3 in the Supplementary Appendix). The cumulative incidence of postherpetic neuralgia was lower in the HZ/su group
than in the placebo group, in both the modified and the total vaccinated cohorts (Fig. 3).
The incidence of postherpetic neuralgia among
HZ/su recipients with breakthrough herpes zoster did not differ significantly from that among
placebo recipients (12.5% and 9.6%, respectively; P = 0.54).
Reactogenicity

In ZOE-70, a total of 1025 participants (7.4%)
were randomly assigned to the reactogenicity
subgroup (512 HZ/su recipients and 513 placebo
recipients). In this subgroup, solicited reports of
reactions (“solicited reactions”) that occurred
within 7 days after each vaccination were noted
in 79.0% of HZ/su recipients and in 29.5% of
placebo recipients (Table 2).
Injection-site solicited reactions occurred in
74.1% of HZ/su recipients and in 9.9% of placebo
recipients; most reactions were mild to moderate
in intensity. Grade 3 injection-site solicited reactions were reported in 8.5% of HZ/su recipients
and in 0.2% of placebo recipients. Systemic solicited reactions occurred in 53.0% of HZ/su recipients and in 25.1% of placebo recipients
(grade 3 reactions were reported in 6.0% and
2.0%, respectively). In the HZ/su group, the most
common injection-site reaction was pain (in 68.7%
of HZ/su recipients) and the most common systemic reaction was fatigue (in 32.9%). The reactions were transient, with median durations of
2 to 3 days for injection-site reactions, 1 to 2 days
for systemic reactions, and 1 to 2 days for grade 3
reactions (Table S3 in the Supplementary Appendix).
The overall frequency and severity of the solicited reactions did not increase significantly after
the second dose (Fig. S4 in the Supplementary
Appendix). Solicited reactions tended to be less
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Figure 2. Risk of Development of Herpes Zoster after Vaccination.
Shown are the Kaplan–Meier estimates of the cumulative incidence (expressed as the percentage of the participants at risk) of the development of herpes zoster during the period from 30 days after receiving the second dose of HZ/su or placebo to the end of follow-up
among participants 70 years of age or older. Because of the declining numbers of participants at risk, the Kaplan–Meier curves have
been truncated at 48 months after the second dose of HZ/su. Some cases occurred after 48 months. In each panel, the inset shows the
same data on an expanded y axis.

frequent among participants 80 years of age or Safety
older than among those 70 to 79 years of age In ZOE-70, during a mean follow-up period of
(Table S4 in the Supplementary Appendix).
4.0 years, the overall incidence of serious adverse
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Figure 3. Risk of Development of Postherpetic Neuralgia after Vaccination in the Pooled Population.
Shown are the Kaplan–Meier estimates of the cumulative incidence (expressed as the percentage of the participants at risk) of the de
velopment of postherpetic neuralgia during the period from 30 days after receipt of the second dose of HZ/su or placebo to the end of
follow-up in the pooled ZOE-70 and ZOE-50 populations. Because of the declining numbers of participants at risk, the Kaplan–Meier
curves have been truncated at 48 months after the second dose of HZ/su. Some cases occurred after 48 months. In each panel, the inset
shows the same data on an expanded y axis.

events and potential immune-mediated diseases ents and in 17.5% of placebo recipients, and powere similar in the two study groups; serious tential immune-mediated diseases occurred in
adverse events occurred in 16.6% of HZ/su recipi- 1.3% of HZ/su recipients and in 1.4% of placebo
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recipients (Table 2). Serious adverse events that
were considered by the investigators to be related to the trial intervention occurred in 12 HZ/su
recipients (0.2%) and in 8 placebo recipients
(0.1%). Overall, 426 participants in the HZ/su
group (6.1%) and 459 participants in the placebo
group (6.6%) died. One death was considered
by the investigators to be related to the trial
intervention: a 90-year-old participant with preexisting thrombocytopenia had acute myeloid
leukemia diagnosed 75 days after the first dose
of HZ/su and died from neutropenic sepsis 97 days
after vaccination, without having received the
second dose.

Discussion
Herpes zoster and its complications, especially
postherpetic neuralgia, are associated with substantial morbidity among older adults. In this
phase 3 trial, two doses of HZ/su administered
2 months apart had a vaccine efficacy of 89.8%,
as compared with placebo, in reducing the risk
of herpes zoster among adults 70 years of age or
older. A similar vaccine efficacy in reducing the
risk of postherpetic neuralgia was shown in the
pooled analysis.
The results of the current trial, which involved a population of adults 70 years of age or
older, are consistent with those of a parallel
study involving adults 50 years of age or older
(ZOE-50), in which HZ/su was shown to have an
efficacy of 97.9% for the prevention of herpes
zoster in a smaller population of adults 70 years
of age or older.26 Vaccine efficacy for the prevention of herpes zoster in adults 70 years or age or
older did not differ significantly between these
two studies.
ZOE-50 and ZOE-70 were conducted in an
identical manner at the same sites, and participants 70 years of age or older were randomly
assigned to one of the two studies. Therefore,
pooling data from both studies was justified and
provided a more robust assessment of vaccine
efficacy against herpes zoster; it also allowed for
an analysis of vaccine efficacy against postherpetic neuralgia, an analysis that would not otherwise have been feasible given the low risk of
postherpetic neuralgia among the participants
in each individual study. Vaccine efficacy against
herpes zoster in the pooled analysis was very
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similar in the two age groups studied (91.3%
among participants 70 to 79 years of age and
91.4% among participants ≥80 years of age),
which indicated that there was no decline in efficacy with age. This finding is consistent with
the results of ZOE-50, in which vaccine efficacy
against herpes zoster was found to be similar in
all age groups (50 to 59, 60 to 69, and ≥70 years
of age), but it contrasts with the efficacy of the
approved live attenuated vaccine (Zostavax), which
was found to decline with increasing age: 70%
in adults 50 to 59 years of age, 64% in adults 60
to 69 years of age, 41% in adults 70 to 79 years
of age, and 18% in adults 80 years of age or
older.24,25
In the Shingles Prevention Study, the live attenuated herpes zoster vaccine appeared to provide additional protection against postherpetic
neuralgia beyond preventing herpes zoster
(among adults 60 years of age or older, 51% vaccine efficacy against herpes zoster vs. 67% vaccine efficacy against postherpetic neuralgia).19
Protection against postherpetic neuralgia in our
trials appeared to be driven by the lower incidence of herpes zoster (91.3% vaccine efficacy
against herpes zoster vs. 88.8% vaccine efficacy
against postherpetic neuralgia in the pooled
population of adults ≥70 years of age); there is
no evidence for additional efficacy against post
herpetic neuralgia among HZ/su recipients with
breakthrough herpes zoster. However, although
the number of postherpetic neuralgia cases in
HZ/su recipients was limited because of the high
vaccine efficacy against herpes zoster, which
precludes a robust assessment of HZ/su vaccine
efficacy against postherpetic neuralgia among
persons with breakthrough herpes zoster, our
results indicate that vaccination with HZ/su substantially reduces the overall risk of postherpetic
neuralgia among older adults.
The vaccine efficacy against herpes zoster
was 87.9% in the fourth year after vaccination.
Although the point estimate for vaccine efficacy
against herpes zoster was higher in the first
year after vaccination than in subsequent years,
this difference was not significant. Therefore, we
cannot make conclusions regarding the magnitude of a potential decline in efficacy. Additional follow-up is required to assess the persistence of HZ/su-induced protection over a
longer period.
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Table 2. Vaccine Reactogenicity and Safety Overall.
Time Period and Event

HZ/su Group

Placebo Group

no. of participants/
total no.

% (95% CI)

no. of participants/
total no.

% (95% CI)

399/505

79.0 (75.2–82.5)

149/505

29.5 (25.6–33.7)

Within 7 days after vaccination in the reactogenicity subgroup*
Any reaction
Grade 3 reaction†

60/505

11.9 (9.2–15.0)

10/505

2.0 (1.0–3.6)

374/505

74.1 (70.0–77.8)

50/505

9.9 (7.4–12.8)

Pain

347/505

68.7 (64.5–72.7)

43/505

8.5 (6.2–11.3)

Redness

198/505

39.2 (34.9–43.6)

5/505

1.0 (0.3–2.3)

Swelling

114/505

22.6 (19.0–26.5)

2/505

0.4 (0.0–1.4)

Injection-site reaction

Grade 3 injection-site reaction†
Systemic reaction

43/505

8.5 (6.2–11.3)

267/504

53.0 (48.5–57.4)

127/505

1/505

25.1 (21.4–29.2)

0.2 (0.0–1.1)

Fatigue

166/504

32.9 (28.8–37.2)

77/505

15.2 (12.2–18.7)

Myalgia

157/504

31.2 (27.1–35.4)

41/505

8.1 (5.9–10.9)

Headache

124/504

24.6 (20.9–28.6)

55/505

10.9 (8.3–13.9)

Shivering

75/504

14.9 (11.9–18.3)

22/505

4.4 (2.7–6.5)

Fever

62/504

12.3 (9.6–15.5)

13/505

2.6 (1.4–4.4)

Gastrointestinal symptoms

55/504

10.9 (8.3–14.0)

40/505

7.9 (5.7–10.6)

30/504

6.0 (4.1–8.4)

10/505

2.0 (1.0–3.6)

1153/6950

16.6 (15.7–17.5)

1214/6950

17.5 (16.6–18.4)

Grade 3 systemic reaction†
Throughout the study period in the total vaccinated cohort‡
Serious adverse event
Serious adverse event considered as related to
vaccination §
Potential immune-mediated disease
Death

12/6950

0.2 (0.1–0.3)

8/6950

0.1 (0.0–0.2)

92/6950

1.3 (1.1–1.6)

97/6950

1.4 (1.1–1.7)

426/6950

6.1 (5.6–6.7)

459/6950

6.6 (6.0–7.2)

*	Reports within 7 days after vaccination in the reactogenicity subgroup (a randomly selected subgroup of age-stratified participants) were
solicited reports of injection-site reactions (pain, redness, and swelling) and systemic reactions (fatigue, fever, gastrointestinal symptoms,
headache, myalgia, and shivering).
†	Redness and swelling at the injection site were scored as 0 if the affected area was less than 20 mm in diameter, 1 if the affected area was
20 to 50 mm, 2 if the affected area was more than 50 to 100 mm, and 3 if the affected area was more than 100 mm. Fever was scored as 0 for
a body temperature lower than 37.5°C, 1 for 37.5°C to 38.0°C, 2 for 38.1°C to 39.0°C, and 3 for higher than 39.0°C (the preferred route for recording temperature was oral). All other symptoms were scored as 0 for absent, 1 for easily tolerated, 2 for interferes with normal activity,
and 3 for prevents normal activity. Serious adverse events were defined as events that resulted in death, were life-threatening, led to hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, or caused a congenital anomaly or birth defect in
the child of a participant.
‡	Details are provided in Tables S5 through S8 in the Supplementary Appendix.
§	The serious adverse events considered by the investigator to be related to the trial intervention were lymphadenitis, acute myocardial infarction, ulcerative colitis, acute pancreatitis, administration-site erythema, administration-site pain, chills, pyrexia, allergic granulomatous angiitis,
bacterial arthritis, erysipelas, herpes zoster oticus, eczema, neutropenic sepsis, and acute myeloid leukemia in the HZ/su group and polymyalgia rheumatica, gastric adenocarcinoma, cerebral infarction, cerebrovascular accident, the Guillain–Barré syndrome, loss of consciousness, syncope, and glomerulonephritis in the placebo group. Some participants had more than one event.

Solicited reports of injection-site and systemic
reactions were more common among HZ/su recipients than among placebo (saline) recipients,
a finding consistent with results of previous

n engl j med 375;11

studies.23,25,26 The reactions were generally mildto-moderate in intensity and were transient, and
neither their frequencies nor their severity increased significantly after the second dose.
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Despite the higher reactogenicity observed with
HZ/su, adherence to receiving the second dose
was similar to that with placebo (approximately
95%). The frequency of solicited reports of injection-site and systemic reactions decreased slightly
with age.
No safety concerns associated with HZ/su
were identified in the current trial. The overall
incidences of potential immune-mediated diseases, serious adverse events, and deaths were
similar in the vaccine and placebo groups. One
death in the HZ/su group was considered by the
local investigator to be related to the vaccination; however, serious adverse events considered
by the investigators to be related to vaccination
were similar in frequency between the two study
groups. In addition, reported serious adverse
events were consistent with general expectations
for this older population.29 These results are
consistent with those of ZOE-50, in which no
safety concerns related to vaccination with HZ/su
were identified.26 Furthermore, participants from
the placebo groups in ZOE-50 and ZOE-70 are
currently being offered vaccination with HZ/su
under a separate protocol (ClinicalTrials.gov number, NCT02690207). This open-label, single-group
study will allow us to collect additional safety data.
As we found in adults 50 years of age or
older,26 the efficacy of HZ/su indicates that immune responses directed against a single VZV
antigen (glycoprotein E) are capable of protecting against herpes zoster in adults 70 years of age
or older. Although the immunologic basis for
protection against herpes zoster is not known,
VZV-specific CD4+ T cells are believed to play a
central role.30,31 Accordingly, HZ/su induces strong
glycoprotein E–specific immune responses, including CD4+ T-cell responses, that are preserved with age.20,24 Moreover, the robustness of
the immune responses to glycoprotein E are attributable to the action of the AS01B adjuvant
system, which has also been shown to enhance
CD4+ T-cell and humoral immune responses to
subunit antigens from other pathogens.32,33 To-
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gether, these results suggest that such adjuvants
have the potential to improve the efficacy of
vaccines that are intended for use in older adults
and other populations that may otherwise have
a lower response to vaccination.
In conclusion, in ZOE-70 we found that the
adjuvanted subunit HZ/su vaccine reduced the
risk of herpes zoster and postherpetic neuralgia
among adults 70 years of age or older, without
substantial safety concerns.
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